# N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07639450/  
OnCo record `nct07639450` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Hefei Xinzhu Biological Technology Co., Ltd., now recruiting.

## Summary

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07639450 by Hefei Xinzhu Biological Technology Co., Ltd., with 114 participants planned, started 2026-06-15 and due to reach its primary completion in 2028-08-31. Interventions recorded: N-3C01(Q2W), N-3C01(Q3W), N-3C01 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07639450
- Phase: 1/2
- Setting: A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors
- Sponsor: Hefei Xinzhu Biological Technology Co., Ltd.
- Enrolled: 114

## Sources

- ClinicalTrials.gov NCT07639450: https://clinicaltrials.gov/study/NCT07639450

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07639450.json